

CURRICULUM VITAE FOR JORGE A. GARCIA, MD, FACP.

PERSONAL INFORMATION

Name: Garcia, Jorge A.

Education

School: Calasanz College

Degree: B.S

Dates: 1979-1985

School: Colombian Navy Academy

Degree: Naval Cadet

Dates: 1986-1987

School: Colombian School of Medicine (Universidad el Bosque)

Degree: M.D.

Dates: 1988-1994

Post-Graduate Training

Institution: Cleveland Clinic

Position: Leading in Health Care Fellow

Dates: 2009-2010

Institution: University of California San Francisco

Position: Hematology/Medical Oncology Fellowship

Dates: 2001-2004

Institution: Albert Einstein College of Medicine

Position: Medicine Internship and Residency

Dates: 1998-2001

Institution: Harvard Medical School

Position: Research Fellow - Cancer Biology

Dates: 1995-1998

PROFESSIONAL APPOINTMENTS

Position/Rank: Chair, Division of Solid Tumor Oncology

Institution/Institute/Department: University Hospitals Seidman Cancer Center. Cleveland, OH.

Dates: 2020-

Position/Rank: Director, Clinical Research Office

Institution/Institute/Department: Case Comprehensive Cancer Center. Cleveland, OH.

Dates: 2018-2019

Position/Rank: Director, GU Oncology Research Program

Institution/Institute/Department: Cleveland Clinic Taussig Cancer Institute. Cleveland, OH.

Dates: 2019

Position/Rank: Director, Advanced Prostate Cancer Research Program

Institution/Institute/Department: Cleveland Clinic Taussig Cancer Institute. Cleveland, OH.

Dates: 2014-2019

Position/Rank: Staff Physician, Hematology/Medical Oncology
Institution/Institute/Department: Cleveland Clinic Taussig Cancer Institute. Cleveland, OH.
Dates: 2005-2019

Position/Rank: Staff Physician, Urology
Institution/Institute/Department: Cleveland Clinic Glickman Urological & Kidney Institute. Cleveland, OH.
Dates: 2005-2019

Position/Rank: Staff Physician, Medicine
Institution/Institute/Department: John Muir/Mt. Diablo Health System. Concord, CA
Dates: 2003-2005

Position/Rank: Fellow in Urologic Oncology
Institution/Institute/Department: UCSF Comprehensive Cancer Center
Dates: 2003-2004

Position/Rank: Fellow in Hematology and Medical Oncology
Institution/Institute/Department: University of California San Francisco and affiliated hospitals
Dates: 2001-2004

Position/Rank: Visiting Resident in Medicine
Institution/Institute/Department: Memorial Sloan Kettering Cancer Center, New York, NY.
Dates: 2000-2001

Position/Rank: Resident in Medicine
Institution/Institute/Department: Jacobi Medical Center/Montefiore Medical Center, Bronx, NY.
Dates: 1999-2001

Position/Rank: Visiting Resident in Medicine
Institution/Institute/Department: Beth Israel Deaconess Medical center, Boston, MA.
Dates: 1999

Position/Rank: Intern in Medicine
Institution/Institute/Department: Jacobi Medical Center/Montefiore Medical Center, Bronx, NY.
Dates: 1998

Position/Rank: Research Fellow in Medicine
Institution/Institute/Department: Beth Israel Deaconess Medical Center, Brookline, MA.
Dates: 1995-1998

Position/Rank: Postgraduate Intern - Hospitalist
Institution/Institute/Department: Department of Health, Bogota, Colombia
Dates: 1994-1995

ACADEMIC APPOINTMENTS

Position/Rank: Professor of Medicine and Urology
Institution/Institute/Department: Case Western Reserve University
Dates: 2020-

Position/Rank: Associate Professor of Medicine
Institution/Institute/Department: Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH.
Dates: 2016-2019

Position/Rank: Assistant Professor of Medicine
Institution/Institute/Department: Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH.
Dates: 2006-2016

Position/Rank: Urologic Oncology Research Fellow
Institution/Institute/Department: UCSF Comprehensive Cancer Center, San Francisco, CA.
Dates: 2003-2004

Position/Rank: Clinical Fellow in Hematology and Medical Oncology
Institution/Institute/Department: University of California San Francisco, San Francisco, CA.
Dates: 2001-2004

Position/Rank: Intern and Resident in Medicine
Institution/Institute/Department: Albert Einstein College of Medicine, Bronx, NY
Dates: 1998-2001

Position/Rank: Research Fellow in Medicine
Institution/Institute/Department: Harvard Medical School, Boston, MA.
Dates: 1995-1998

CERTIFICATION AND LICENSURE

Name of Board: Ohio
Date of Certificate: September 3, 2004
Licensure State/Number: 35.085035
Date Issued: 2004-Current and active

Name of Board: California
Date of Certificate: June 21, 2001
Licensure State/Number: A75239
Date Issued: 2001-N/A (expired)

Name of Board: New York
Date of Certificate: June 1998
Licensure State/Number: N/A
Date Issued: 1998-N/A (expired)

DEA: BG7994646 – Active

HONORS AND AWARDS

2020- George and Edith Richman Distinguished Scientist Chair
University Hospitals Seidman Cancer Center, Case Western Reserve University

2017-2019 The Kerscher Family Chair for Clinical Prostate Cancer Research
Cleveland Clinic

2010-2019 Best Doctors in Cleveland

2009-Current Best Doctors in America

2009 Fellow, American College of Physicians (FACP)

2006 Best Hispanic Leader. Cuyahoga County, Ohio.

2004 American Society of Clinical Oncology (ASCO), Young Investigator Award (YIA)

2003 ASCO/American Association of Cancer Research (AACR), Methods in Clinical Cancer
Research

2002 Amgen Educational Award, University of California, San Francisco

2000	Selected as “Chief Resident” for years 2001-2002, East Campus, Albert Einstein College of Medicine
1999	Outstanding Resident Award, East Campus, Albert Einstein College of Medicine
1998	Leo M. Davidoff Society Teaching Award, Albert Einstein College of Medicine

MEMBERSHIP IN PROFESSIONAL SOCIETIES

2005- Current	Active Member SWOG GU committee
2002- Current	Active Member, American Association of Cancer Research
2001- Current	Member, American Society of Clinical Oncology
2001- 2004	Member, Northern California Oncology Group
1998- Current	Member, American Medical Association
1998- Current	Associate Member, American College of Physicians

PROFESSIONAL SERVICES

Editorial Boards - current

2019-	Associate Editor for Drugs in Context
2017-	Associate Editor for Clinical Genitourinary Cancer
2015-2019	Specialty Editor - Bladder Cancer. ASCO Cancer. Net
2015-2019	Specialty Editor - Prostate Cancer. ASCO Cancer. Net
2013-	Ad Hoc Reviewer, Clinical Cancer Research
2013-	Ad Hoc Reviewer, Molecular Cancer Therapeutics
2013-	Ad Hoc Reviewer, Journal Clinical Oncology
2011-	Editorial Board, Therapeutic Advanced in Medical Oncology
2011-	Editorial Board, Frontiers in Genitourinary Oncology
2011-	Editorial Board, CML Kidney Cancer
2010-	Ad Hoc Reviewer, Urologic Oncology
2010-	Ad Hoc Reviewer, Annals of Oncology
2010-	Ad Hoc Reviewer, Journal of Urology
2010-	Ad Hoc Reviewer, Annals of Urology
2009-	Ad Hoc Reviewer, British Journal of Cancer
2009-	Ad Hoc Reviewer, Clinical and Experimental Medicine
2008-	Ad Hoc Reviewer, Cancer Chemotherapy and Pharmacology
2008-	Ad Hoc Reviewer, Cancer
2007-	Ad Hoc Reviewer, Urology
2007-	Ad Hoc Reviewer; British Journal of Urology
2007-	Ad Hoc Reviewer, Clinical Genitourinary Cancer
2007-	Ad Hoc Reviewer, Biologics: targets & therapy

COMMITTEE SERVICE

2019-	Member, Oncology Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA)
2017- 2018	Chair, NCCN Guidelines – Prostate Cancer. Case Comprehensive Cancer Center
2016-2017	Chair Protocol Review Committee Board Review (PRMC). Case Comprehensive Cancer Center.
2014-2015	Renal Cell Cancer Track Committee Member ASCO GU 2015
2014-2015	Co-Chair Protocol Review Committee Board Review (PRMC). Case Comprehensive Cancer Center.
2011-2013	Program Committee International Kidney Cancer Symposium
2011-2015	SUO-CTC Board of Directors and the Renal Organ Site Committee
2010-2015	Co-Director, Prostate Cancer Program, Case Comprehensive Cancer Center
2010-	Director, GU Medical Oncology Prostate Cancer Clinical Research Program. Cleveland Clinic Taussig Cancer Institute

2006-	Relevance Reviewer American Board of Internal Medicine “Medical Oncology”
2005-	Full Member, PRMC. Case Comprehensive Cancer Center
2005-	Full Member Protocol Review Committee. Cleveland Clinic Taussig Cancer Institute
2003-04	Member, GU-ONC Protocol Review Committee. UCSF Comprehensive Cancer Center
2003-04	Member, GU-ONC Tissue Core Protocol Review Committee. UCSF Comprehensive Cancer Center
2003-04	Member, Genitourinary Protocol Review Committee. UCSF Comprehensive Cancer Center
2003-04	Member, GU-ONC Tissue Core Protocol Review Committee. UCSF Comprehensive Cancer Center

PRESENTATIONS / VISITING PROFESSOR (selected ONLY for years 2010-2020)

10/20	Opinions in Bladder Cancer: An Interactive Local Virtual Workshop. Aptitude Health *CME*
05/20	A 69-Year-Old Man with Advanced Castrate-Resistant Prostate Cancer. Case Management. Targeted Oncology *CME*
05/20	Importance of Bone Health Agents in mCRPC Management. Targeted Oncology *CME*
04/20	Existing Therapies for the Management of men with M0CRPC Webinar. Cairo, Egypt.
04/20	Managing Men with mCRPC: Targeted Oncology Webinar. *CME*
01/20	Contemporary Management of M0CRPC. Cartagena, Colombia. *CME*
01/20	ASCO Advantage Program- Prostate Cancer. *CME*
11/19	Expert Perspective Tumor Board – Prostate Cancer. *CME*
10/19	Bone Health in Advanced Prostate Cancer – AMGEN Podcast
09/19	Managing M0 CRPC Patients on AR Inhibitors. Targeted Oncology *CME*
01/19	ESMO 2018: Latest Research in Treating Kidney and Prostate Cancers. Cancer.Net Podcasts *CME*
11/18	Director, Cleveland Clinic 18 th Annual GU Oncology Meeting – Focused on Prostate Cancer. Cleveland, OH *CME*
08/18	Best of ASCO 2018 Annual Meeting. Genitourinary (Non-prostate) Cancer. Chicago, IL. *CME*
05/18	Tumor Board: Prostate Cancer – Panelist. AUA 2018 Plenary presentation. San Francisco, CA. *CME*
01/18	Cleveland Clinic Taussig Cancer Institute Hematology/Oncology Cancer Center Rounds: New Paradigms in the Management of CRPC. Cleveland, OH. *CME*
12/17	Director. 17th Annual Multidisciplinary Genitourinary Oncology Course: Focus on Renal/Bladder and Testis Cancer. *CME*
11/17	Chemotherapy vs. Oral Therapy for Advanced Castration-Sensitive PCa. 8 th SOGUG Scientific Symposium. Madrid, Spain. *CME*
11/17	Role of Immune checkpoint inhibition in Bladder Cancer. VGHTPE (Taipei Veterans General Hospital) Taipei, Taiwan. *CME*
11/17	How to Optimize IO-based therapy in CDDP-resistant Metastatic Urothelial Carcinoma. NTUH (National Taiwan University) Taipei, Taiwan. *CME*
09/17	Optimal Management of Men with Metastatic Hormone-Sensitive Prostate Cancer (Internet Live) *CME*
09/17	Current Approaches to the Treatment of Metastatic Castration-Resistant Prostate Cancer (Internet Live) *CME*
05/17	How to Optimize Treatment in CRPC: Use of Molecular Factors. VHIO Symposium: New Challenges in Uro-oncology. Barcelona, Spain. *CME*
05/17	How to Choose Second-line Therapy in mRCC: Use of Oral Agents. VHIO Symposium: New Challenges in Uro-oncology. Barcelona, Spain. *CME*
05/17	Debates in Immunotherapy: Immunotherapy in TCC: Treatment for all. VHIO Symposium: New Challenges in Uro-oncology. Barcelona, Spain. *CME*

- 05/17 Debates in Immunotherapy: Immunotherapy in TCC: Sequential Therapy in 2017. VHIO Symposium: New Challenges in Uro-oncology. Barcelona, Spain. ***CME***
- 04/17 Genitourinary Oncology Updates: Management of CRPC and Advanced RCC. Dominican Society of Hematology and Medical Oncology. Santo Domingo. ***CME***
- 11/16 Recent Advances in the Management of Advanced Prostate Cancer. Promedica Cancer Institute, Sylvania, Ohio. ***CME***
- 11/16 Emerging Role of novel Radionucleotide-based therapy in the management of mCRPC: 7th SOGUG Scientific Symposium. Madrid, Spain. ***CME***
- 11/16 Onc Live Peer Exchange: Castration Resistant Prostate Cancer. ***CME***
- 11/16 Director, 16th Annual Multidisciplinary Genitourinary Oncology Course. Cleveland Clinic. Cleveland, Ohio. ***CME***
- 10/16 Integral Evaluation of Patients with Metastatic Castration-Resistant Prostate Cancer. 34th National Oncology Meeting SMeO. Sociedad Mexicana de Oncología, A.C. Tijuana, Baja California. ***CME***
- 10/16 Emerging Role of Chemotherapy in Advanced Prostate Cancer. Annual Oncology Society Meeting. San Juan, Puerto Rico. ***CME***
- 10/16 Current Management of Advanced RCC: Present and Future. Annual Oncology Society Meeting. San Juan, Puerto Rico. ***CME***
- 08/16 CRPC: Appropriate Sequence and Timing for Chemotherapy. Congreso Nacional de Hemato-Oncología. Antigua, Guatemala. ***CME***
- 05/16 Management of Advanced Prostate Cancer: Various clinical modules addressing various aspects of CRPC.II Reunión de actualización en CP: Santiago, Chile. ***CME***
- 03/16 Management of Advanced Prostate Cancer. Edwards Comprehensive Cancer Center. Cabell Huntington Hospital. Huntington, WV ***CME***
- 03/16 Second-line therapy for mRCC: Management and Future Challenges. VII International Uro-oncology Congress. Sao Paulo, Brazil. ***CME***
- 01/16 Incorporating Biomarkers in the Clinical Management of GU Cancers: Present and Future. Best of GU. Simposio Científico SOGUG ***CME***
- 11/15 Onc Live Peer Exchange: Castration Resistant Prostate Cancer. ****CME***
- 11/15 Advanced Prostate Cancer: Bench to Clinic and Future developments. Florida Hospital Cancer Center. Orlando, FL. ***CME***
- 10/15 Castration Resistant Prostate Cancer: Emerging Role of Novel Radio nucleotides. Vall D'Hebron Workshop in Advanced Prostate Cancer. Barcelona, Spain. ***CME***
- 10/15 Emerging Trends in Castration Resistant Prostate Cancer: A Multidisciplinary Approach. Hospital Ramon y Cajal. Madrid, Spain. ***CME***
- 09/15 Novel AR Inhibitors in CRPC. International Oncology Meeting. Sao Paulo, Brazil. ***CME***
- 03/15 Challenges in the Management of Advanced Prostate Cancer. University of Minnesota. Minneapolis, MN. ***CME***
- 10/14 Immunotherapy in Advanced RCC: 2004 Update. Second Cleveland-Vall D'Hebron Workshop in Renal Cell Carcinoma. Barcelona, Spain. ***CME***
- 11/13 Earlier Use of Novel Agents in PCa: Logical but Complicated Process. 13th Annual Multidisciplinary Genitourinary Oncology Course. Cleveland, OH. ***CME***
- 09/13 Recent Progress in the Management of RCC. Aultman 13th Annual Cancer Conference. Canton, OH. ***CME***
- 08/13 Preceptorship Program on Prostate Cancer. Director of Activity. Cleveland Clinic. Cleveland, OH. ***CME***
- 07/13 Castrate Resistant Prostate Cancer: ASCO Tumor Boards. ASCO Virtual Site. ***CME***
- 06/13 Challenges in Treating Renal Cell Carcinoma. Genesis Health Care System Medicine Grand Rounds. Zanesville, OH. ***CME***

- 06/13 ASCO 2011 Update: GU Malignancies. Cleveland Clinic/University Hospitals of Cleveland. Cleveland, OH. ***CME***
- 05/13 Challenges in Treating Renal Cell Carcinoma. Community Hospital Medicine Grand Rounds. Munster, IN. ***CME***
- 01/13 Management of CRPC: The Renaissance of and old target. Cleveland Clinic Medicine Grand Rounds. Cleveland, OH. ***CME***
- 11/12 Current Management of Advanced Germ Cell Tumors. Colombian Society of Medical Oncology Meeting. Medellin, Colombia. ***CME***
- 11/12 Controversies on ADT in Advanced Prostate Cancer. 12th Annual Multidisciplinary Genitourinary Oncology Course. Cleveland, OH. ***CME***
- 11/12 Adrenal inhibition in CRPC: Novel agents. Mexico Society of Urology Meeting. Puerto Vallarta, Mexico. ***CME***
- 10/12 How should you choose second line therapy for mRCC. 11th International Kidney Cancer Symposium. Chicago, IL. ***CME***
- 09/12 Selection and Sequencing of Therapies for Advanced RCC: Analyzing the Data. Personalized Care in Solid Tumor Oncology: Transforming Aspirations into Reality. Sao Paulo, Brazil. ***CME***
- 06/12 ASCO 2012 Update: GU Malignancies. Cleveland Clinic/University Hospitals of Cleveland. Cleveland, OH. ***CME***
- 06/12 ASCO 2012 Update: Renal Cell Carcinoma. Best of ASCO. Florida Hospital/ASCO. Orlando, Florida. ***CME***
- 05/12 Management of Castration-resistant Prostate Cancer. Latin American Oncology meeting. Panama, Panama. ***CME***
- 11/11 Clinical Implications of the Biology of CRPC. 11th Annual Multidisciplinary Genitourinary Oncology Course. Cleveland, Ohio. ***CME***
- 10/11 Sequential VEGF inhibition in VEGF Refractory RCC. 10th International Kidney Symposium. Chicago, IL. ***CME***
- 10/11 IV Inter American Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies: GU Malignancies. Buenos Aires, Argentina. ***CME***
- 06/11 ASCO 2011 Update: GU Malignancies. Cleveland Clinic/University Hospitals of Cleveland. Cleveland, OH. ***CME***
- 06/11 ASCO 2011 Update: Renal cell Cancer. Florida Hospital Cancer Institute (FHCI). Orlando, FL. ***CME***
- 04/11 Bisphosphonates or RANK-ligand inhibitors: Options to reduce skeletal related events (SREs) in Metastatic Castration-resistant Prostate Cancer. American Association of Cancer Research (AACR) 2011. Orlando, FL. ***CME***
- 04/11 Current Management of Advanced RCC. Sociedad Medica Oncologica de Mexico. Mexico D.F, Mexico. ***CME***
- 03/11 Contemporary Management of Advanced Prostate Cancer. Huron Hospital Medicine Grand Rounds. Cleveland, Ohio. ***CME***
- 11/10 Prognostic Factors and Mechanisms of Resistance in Advanced RCC. SOGUG Meeting. Madrid, Spain. ***CME***
- 10/10 Perioperative VEGF-Targeted therapy in Advanced RCC. 1st Niagara Kidney Cancer Symposium. Lewiston, NY. ***CME***
- 10/10 Current Data and Ongoing Trials in VEGF Therapy Resistant Patients. 9th International Kidney Symposium. Chicago, IL. ***CME***
- 07/10 Management of Advanced RCC: Third-line therapy and beyond. 10th International Congress on Genitourinary Malignancies. Washington, DC. ***CME***
- 06/10 2010 Annual ASCO Review (GU Oncology). Florida Hospitals. Orlando, Florida. ***CME***

- 06/10 Seventh Annual Oncology Review (GU Oncology). Vanderbilt-Ingram Cancer Center. Nashville, Tennessee. ***CME***
- 03/10 Argentinean Symposium of Genitourinary Tumors. Buenos Aires, Argentina. ***CME***
- 02/10 Advances in Targeted Molecular Therapy for Renal Cell Carcinoma: Evolving Therapeutic Paradigms. Baptist Hospital Grand Rounds. Pensacola, Florida. ***CME***
- 02/10 Advances in Targeted Molecular Therapy for Renal Cell Carcinoma: Evolving Therapeutic Paradigms. Genesis Healthcare System/Good Samaritan Hospital Grand Rounds. Zanesville, Ohio. ***CME***

DIRECT TRAINEES / MENTEES

1. Toni Choueiri, MD – Director Lank Urological Institute, Dana Farber Cancer Institute. Harvard Medical School
2. Jenny Kim, MD – GU Medical Oncologist (RCC focus), Johns Hopkins Sidney Kimmel Comprehensive Cancer Center – Currently at pharmaceutical company
3. Daniel Heng, MD, FRCPC – GU Medical Oncologist Tom Baker Cancer Centre in Calgary, Alberta
4. Ila Tamaskar, MD – Medical Oncologist, Metro Hospital, Cleveland, Ohio.
5. Saby George, MD – GU Medical Oncologist, Roswell Park Cancer Institute.
6. Leticia Varella, MD – Beast Cancer Medical Oncologist, Cornell University Hospital, New York, NY
7. Christos Kyriakopolous, MD – GU Medical Oncologist, University of Wisconsin Carbone Cancer Center. Madison, Wisconsin.
8. Adriana Alvarez, MD – Hematology/Medical Oncology Fellow (2014-2017), University Hospitals Cleveland.
9. Hamid Emamekhoo, MD – GU Medical Oncologist, University of Wisconsin Carbone Cancer Center. Madison, Wisconsin.
10. Ao Zhang, CCLCM Medical student (JGarcia – Thesis committee member) Resident Physician Surgery-Prelim & Urology, Cleveland Clinic.
11. Daniel Hettel, CCLCM Medical student (JGarcia –Thesis committee member) Resident Physician Urology Cleveland Clinic.
12. Mohamad Khasawneh, MD – Medical Oncologist. Leonard Lawson Cancer Center. Pikeville, KY
13. Hiral Parekh, MD, MPH. Medical GI Oncologist. UF Health Medical Oncology - Davis Cancer Pavilion. Gainesville, FL
14. Sarmad Sadeghi, MD. Medical GU Oncologist. USC Norris Comprehensive Cancer Center. Los Angeles, CA.
15. Vadim Koshkin, MD – GU Medical Oncologist. UCSF. San Francisco, CA.
16. Haris Zahoor, MD – USC Norris Comprehensive Cancer Center. Los Angeles, CA.
17. Pedro Barata, MD – GU Medical Oncologist, Tulane University. New Orleans, LA.
18. Moshe Ornstein, MD – GU Medical Oncologist. Cleveland Clinic Taussig Cancer Institute. Cleveland, OH.
19. Anita Gul, MD – GU Medical Oncologist, University of Minnesota Masonic Cancer Center, Minneapolis, MN.
20. Iris Sheng, MD - Hematology/Oncology Fellow. Cleveland Clinic Taussig Cancer Institute. Cleveland, OH.

TEACHING ACTIVITIES

1. Cleveland Clinic 2005-2019
 - a. Inpatient Teaching Hospital Rotations
 - i. Four weeks/year on the “Solid Tumor Oncology” inpatient service with daily interactions with medical students, residents and fellows.
 - b. Outpatient GU Oncology
 - i. 2.5 clinic days of GU Oncology with focus in prostate, kidney, testis and bladder cancer.
 - ii. Daily interaction with a permanent clinical hematology/medical oncology and experimental therapeutics fellows
 - c. GU In-patient Consult Services
 - i. All year around in-patient GU consults with daily interactions with medical students, residents and fellows.

2. University Hospitals Seidman Cancer Center
 - a. Inpatient Teaching Hospital Rotations
 - i. Two weeks/year on the “Solid Tumor Oncology” inpatient service with daily interactions with medical students, residents and fellows.
 - b. Outpatient GU Oncology
 - i. 1.5 clinic days of GU Oncology with focus in prostate, kidney, testis and bladder cancer.
 - ii. Daily interaction with a permanent clinical hematology/medical oncology fellows and internal medicine residents.
 - c. GU In-patient Consult Services
 - i. All year around in-patient GU consults with daily interactions with medical students, residents and fellows.

RESEARCH SUPPORT

1. **Grant: Prostate Cancer Research Center of Excellence – Cleveland Clinic Lerner Research Institute**
 Title: Defining the underlying clinical and biochemical behavior of the lethal form of prostate cancer
 Level of Support: \$ 900,000
 Role: Co-PI (10% effort)
2. **Grant: Prostate Cancer Foundation Global Treatment Sciences Challenge Award– Cleveland Clinic Lerner Research Institute**
 Title: Exploiting an actionable germ-line biomarker of castration-resistant prostate cancer
 Level of Support: \$1,000,000
 Role: Co-PI (3% effort)
3. **Grant: Pilot Grant Award Case Comprehensive Cancer Center**
 Title: A Phase II Study of BEZ235, an mTOR/PI3K Dual Inhibitor, in Patients with Advanced Renal Cell Carcinoma (RCC) Undergoing Cytoreductive Nephrectomy
 Project Period: 3/2011 -- 3/2012
 Level of Support: \$70,000
 Role: PI
4. **Grant: ASCO Young Investigator Award**
 Title: Enhancement of Prostate Tissue Specific Immune Response after Cytokine Administration
 Project Period: 7/2004 -- 7/2005
 Level of Support: \$35,000
 Role: PI
5. **UH/Seidman Cancer Center Clinical Research Support as Principal Investigator – Selected Only**
CTEP/NCI/COOPERATIVE GROUP/DOD Protocols: Role: PI
 1. ECOG8143/CTEP Intergroup Trial. Principal Investigator. A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC). Ongoing
 2. NRG-GU007. Co-Principal Investigator. Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I).
 3. ECOG8153/CTEP Intergroup Trial. Co-Principal Investigator. Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial.
 4. RTOG3506. Co-Principal Investigator. STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

Selected Pharmaceutical Sponsored Trials: Role: PI

1. AREN1721. Co-Principal Investigator. A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
2. MRK1819. Principal Investigator. MK7902-866 (KEYNOTE-866): A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer
3. MRK3819. Co-Principal Investigator. MK7902-641 A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
4. MRK2819. Co-Principal Investigator. A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
5. SEGE2817. Principal Investigator. Enfortumab Vedotin (ASG-22CE) plus Immune Checkpoint Inhibitor (CPI) Therapy for Urothelial Cancer
6. MRK4819. Co-Principal Investigator. MK7902-921 A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
7. MRK1Y20. Principal Investigator. A Multicenter, Open label, Phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in Follow-up in a pembrolizumab trial.
8. TTX-030-001. Principal Investigator. Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies.
9. DF6002-001. Principal Investigator. A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

6. Cleveland Clinic Taussig Cancer Institute Clinical Research Support as Principal Investigator – Selected Only

CTEP/NCI/COOPERATIVE GROUP/DOD Protocols: Role: PI

1. CTEP/NCI – Principal Investigator. Phase II study of MLN518 in Patients with TKI-refractory metastatic RCC. (CASE10805). Completed
2. E3805/CTEP Intergroup Trial- Principal Investigator SWOG. "CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. Completed
3. CTEP/NCI – Principal Investigator. Protocol # 8872 "A Phase 2 Study of OSI-906 in Patients with Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC). Completed
4. NO1 Consortium – Randomized, Double-Blind, Placebo-Controlled Phase II study of ARQ 197 (tivantinib) in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. Completed
5. ALLIANCE – Phase III Trial of enzalutamide versus enzalutamide, Abiraterone acetate and prednisone for castration resistant metastatic prostate cancer. Completed
6. DOD Protocol – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer. Open/Accruing

Selected Investigator Initiated Clinical Trials (2018-2019): Role: PI

1. Genentech – Principal Investigator. Phase II Trial of low-dose rIL-2 and Bevacizumab in patients with advanced RCC (IRB7493). Budget: \$196,000.00 Completed

2. Celgene – Principal Investigator. Phase II Trial of Ketoconazole/Hydrocortisone and Revlimid in CRPC patients. (CASE12805) Budget: \$240,879.20 Completed
3. Novartis – Principal Investigator. Randomized phase II study of 2 different doses of Everolimus in locally advanced Prostate Cancer. (CASE21806) Budget: \$203,547.00 Completed
4. Pfizer – Principal Investigator. Phase II trial of neoadjuvant Sunitinib in patients with high-risk muscle-invasive TCC of the bladder. (CASE24806) Budget: \$187,088.00 Completed
5. Pfizer – Principal Investigator. Phase II study of continuous dose Sunitinib for patients with BCG-refractory superficial TCC of the bladder. (CASE3808) Budget: \$204,000.00 Completed
6. Wyeth – Principal Investigator. Phase I/II Study of Temsirolimus and Bevacizumab in chemotherapy-refractory metastatic CRPC. (CASE7808) Budget: \$596,313.00 Completed
7. Genentech – Principal Investigator. Phase I/II Study of Temsirolimus and Bevacizumab in chemotherapy-refractory metastatic CRPC. (CASE7808) Budget: \$203,547.00 Completed
8. Astellas – Principal Investigator. Phase II Study evaluating the efficacy of enzalutamide in patients with high-risk Prostate Cancer who have undergone radical prostatectomy. Budget: \$434,036.00 Completed
9. J&J - Principal Investigator. Phase II The Association between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men with Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy after Treatment with ARN-509 and Leuprolide. Budget: \$550,000.00 Open/Accruing

Selected Pharmaceutical Sponsored Trials: Role: PI

1. Amgen – Principal Investigator. Phase II study of AMG-102 in patients with TKI-refractory advanced RCC. (AMG1806) Budget: \$301,731.00 Completed
2. Imclone – Principal Investigator. Phase II study of IMC1121-B in TKI-refractory advanced RCC. (IMCL1807) Budget: \$192,162.00 Completed
3. Cougar – Principal Investigator. A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. Budget: \$829,287.00 Completed
4. Cougar – Principal Investigator. An Open label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who have Progressed After Taxane-based Chemotherapy. Budget: \$136,650.00 Completed
5. Duke – Principal Investigator. A Randomized Phase II Study of Afinitor (Everolimus) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN). Budget: \$103,521.00 Completed
6. EMR 62242-006 – Principal Investigator. A randomized, double-blind, placebo-controlled, multicenter Phase II trial investigating two doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC). Budget: \$731,788.00 Completed
7. Cougar – Principal Investigator. A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate plus Prednisone in Subjects with Advanced Prostate Cancer without Radiographic Evidence of Metastatic Disease. Budget: \$136,650.00 Completed
8. Bayer – Principal Investigator. Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis. Budget: \$115,271.00 Completed
9. Astex Pharmaceuticals – Principal Investigator. A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone. Budget: \$ 647,550.00 Completed
10. ENDO Pharmaceuticals – Principal Investigator. Safety and Pharmacokinetics of ODM-201 in Patients with Castrate-resistant Prostate Cancer: Open, non-randomised, uncontrolled, multicenter, multiple dose escalation study with a randomised phase II expansion component. Budget: \$ 324,029.00 Completed
11. Medivation - A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy. Budget: \$106,718.00 Completed
12. A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate cancer (BN Immuno Therapeutics) Budget: \$ 298,815.00 Completed

13. A multinational, randomized, double-blind, placebo-controlled phase III efficacy and safety study of ODM-201 in men with high-risk non metastatic castration-resistant prostate cancer (ARAMIS). Budget: \$409,120.00 Closed
14. A Phase 1 / 2, Open –Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion and Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASN001 in Subjects with Metastatic Progressive Castration Resistant Prostate Cancer. Budget: \$470,000.00 Open/Accruing
15. GU 115: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer. Budget: \$172,625 Open/Accruing
16. CO39303: A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated metastatic castrate-resistant prostate cancer. Budget: \$944,002 Open/Accruing
17. IMvigor010: A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection. Budget: \$1,063,362 Open/Accruing
18. PFIZ1816: A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy. Budget: \$2,290,868 Open/Accruing
19. An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Subjects with Metastatic Castration-resistant Prostate Cancer”. Budget: \$417,162
20. TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. Budget: \$246,871

BIBLIOGRAPHY

Peer Reviewed Articles

1. Exley M, **Garcia J**, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+Cd4-CD8-T cells. *J.Exp.Med* 186:109-120, 1997.
2. Exley M, Porcelli S, Furman M, **Garcia J**, Balk S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24J αQ T cell receptor α chains. *J. Exp.Med* 188:867-876, 1998.
3. Kim HS, **Garcia J**, Exley M, Johnson KW, Balk SP, Blumberg RS. CD1d is expressed on the cell surface as a mature glycoprotein in the absence of beta 2-microglobulin. *Gastroenterology*, 116(4): G3249 part 2, 1999.
4. Hyun K, **Garcia J**, Exley M, Johnson K, Balk SP, Blumberg RS. Biochemical characterization of CD1d expression in the absence of Beta 2–microglobulin. *JCB* 274:9289-9225, 1999.
5. Exley M, **Garcia J**, Wilson SB, Spada F, Gerdes D, Tahir SM, Patton KT, Blumberg RS, Porcelli S, Chott A, Balk SP. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. *Immunology* 100:37-47, 2000.
6. Exley MA, Bigley NJ, Cheng O, Shaulov A, Tahir SM, Carter QL, **Garcia J**, Wang C, Patten K, Stills HF, Alt FW, Snapper SB, Balk SP. Innate Immune Response to Encephalomyocarditis virus infection mediated by CD1d. *Immunology* 110:519-526,2003.
7. **Garcia JA**, Weinberg V, and Small EJ. Prior Estrogen therapy as a predictor of response to subsequent Estramustine-based therapy in Androgen-Independent prostate cancer patients. *Clinical Prostate Cancer* 4(2):113-117, 2005.
8. Ciezki JP, Reddy CA, **Garcia J**, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA. PSA Kinetics following Prostate Brachytherapy: The PSA Bounce Phenomenon and Its Implications for PSA Doubling Time. *Int J Radiat Oncol Biol Phys.* 64(2); 512-517; 2006.
9. Choueiri TK, Rini B, **Garcia JA**, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Phase II Study of Lenalidomide in patients with Metastatic Renal Cell Carcinoma. *Cancer* 107(11):2609-2616; 2006

10. Ciezki JP, Reddy CA, **Garcia J**, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA. PSA Bounce and PSA doubling time after prostate brachytherapy: Clinical management insights. *The American Journal of Hematology/Oncology*. 5(9): 545-548; 2006.
11. Rini BI, Tamaskar I, Shaheen P, Salas R, **Garcia J**, Wood L, Reddy S, Dreicer R, Bukowski RM. Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. *JNCI* 99:81-83, 2007.
12. Choueiri TK, Rini BI, **Garcia J**, Baz RC, Abou-Jawde RM, Thakkar SG, Elson, P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. *Ann Oncol* 18:249-255, 2007.
13. **Garcia JA**, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. Evaluation and significance of circulating epithelial cells (CEC) in Hormone- Refractory Prostate Cancer. *BJU Int* 99:519-524, 2007.
14. Choueiri TK, **Garcia JA**, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical Factors Associated with Outcome in Metastatic Renal Cell Carcinoma Patients Treated with VEGF-targeted Therapy. *Cancer* 110(3):543-550, 2007.
15. Tamaskar I, Bukowski R, Elson P, Loachimescu AG, Wood L, Dreicer R, Mekhail T, **Garcia J**, Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. *Ann Oncol* 19(2):265-8, 2008.
16. Tamaskar I, **Garcia JA**, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM. Antitumor Effects of Sunitinib or Sorafenib in Patients with Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-angiogenic Therapy. *J Urol* 179(1):81-6, 2008.
17. Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. Prolonged complete and near complete responses to sunitinib in metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2007 Dec;5(7):446-51.
18. **Garcia JA**, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and Biologic Effects of Neoadjuvant GM-CSF and Thalidomide in High-Risk Localized Prostate Carcinoma. *Clin Cancer Res* 14(10):3052-9, 2008.
19. Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. *Cancer* 113(6):1309-14, 2008.
20. Finke J, Rini BI, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, **Garcia J**, Dreicer R, Bukowski R. Sunitinib reverses type 1 immune suppression and decreases T regulatory cells in renal cell carcinoma patients. *Clin Cancer Res* 14 (20):6674-82, 2008.
21. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, **Garcia JA**, Aydin H, Zhou M, Bukowski RM, Rini BI. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. *J Clin Oncol* 27(2):235-41, 2009.
22. Thomas AA, Rini BI, Lane BR, **Garcia J**, Dreicer R, Klein EA, Novick AC, Campbell SC. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. *J Urol* 181(2):518-23, 2009.
23. Heng DY, Chi KN, Murray N, Jin T, **Garcia JA**, Bukowski RM, Rini BI, Kollmannsberger C. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. *Cancer* 115(4):776-83, 2009.
24. Weight CJ, **Garcia JA**, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ. Lack of Pathologic Down-Staging with Neoadjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Contemporary Series. *Cancer* 115(4):792-9, 2009.
25. Shepard DR, Dreicer R, **Garcia J**, Elson P, Magi-Galluzzi C, Raghavan D, Stephenson AJ, Klein EA. Phase II study of neoadjuvant Abraxane in high-risk Prostate cancer patients undergoing radical prostatectomy. *J Urol* 181(4):1672-7, 2009.
26. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, **Garcia J**, Dreicer R, Bukowski R, Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. *Clin Cancer Res* 15(6):2148-57, 2009.
27. Thomas AA, Rini BI, Stephenson AJ, **Garcia JA**, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC. Surgical Resection of Renal Cell Carcinoma after Targeted Therapy. *J Urol* 182(3):881-6, 2009.
28. Rini BI, **Garcia JA**, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A Phase I Study of Bevacizumab in Combination with Sunitinib. *Clin Cancer Res*. 2009 Oct 1;15(19):6277-83
29. Fergany A, Dhar N, Budd GT, Marek Skacel, **Garcia JA**. Primary Extraosseous Ewing Sarcoma of the kidney with level III inferior vena cava thrombus. *Clin Genitourin Cancer*. 2009 Oct 1;7(3):E95-E97.

30. Khan G, Golshayan A, Elson P, Wood L, **Garcia J**, Bukowski R, Rini B. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. *Ann Oncol*. Advance Access published January 20, 2010.
31. Dreicer R, **Garcia J**, Hussain M, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D. Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. *Invest New Drugs*. 2011 Dec;29(6):1441-8
32. Rini BI, **Garcia JA**, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R. Toxicity of Sunitinib plus Bevacizumab in Renal Cell Carcinoma. *J Clin Oncol*. 2010 Jun 10;28(17):E284-5.
33. Barbastefano J, **Garcia JA**, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI. Association of Percentage of Tumor Burden Removed with Debulking Nephrectomy and Progression Free Survival in Metastatic Renal Cell Carcinoma Patients Treated with VEGF-Targeted Therapy. *BJU Int*. 2010 Nov;106(9):1266-9.
34. **Garcia JA**, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. *Cancer*. 2010 Dec 1;116(23):5383-90
35. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, **Garcia JA**, Knox JJ, Escudier B, Rini BI. Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma Patients. *Cancer*. 2010 Dec 1;116(23):5400-6.
36. **Garcia JA**, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. *BJU Int*. 2011 Feb;107(4):562-70.
37. Karam JA, Rini BI, Varella L, **Garcia JA**, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy Following Targeted Therapy in Patients with Advanced Renal Cell Carcinoma. *J Urol*. 2011 Feb;185(2):439-44.
38. **Garcia JA**, Hutson TE, Shepard D, Elson P, Dreicer R. Phase II Trial of Docetaxel and Gemcitabine in patients with metastatic CRPC. *Cancer*. 2011 Feb 15;117(4):752-7.
39. Basappa NS, Elson P, Golshayan AR, Wood L, **Garcia JA**, Dreicer R, Rini BI. The impact of tumor burden characteristics in metastatic renal cell carcinoma patients treated with sunitinib. *Cancer*. 2011 Mar 15;117(6):1183-9.
40. Ghoneim IA, Micionovic R, Stephenson AJ, **Garcia JA**, Gong MC, Campbell SC, Hansel DE, Fergany AF. Neoadjuvant Systemic Therapy or Early Cystectomy? Single-center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Carcinoma of the Bladder. *Urology*. 2011 Apr;77(4):867-70.
41. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, **Garcia J**, Vogelbaum MA, Finke J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. *Neuro Oncol*. 2011 Jun;13(6):591-9.
42. Schwandt A, **Garcia JA**, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI. Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining. *J Clin Immunol*. 2011 Aug;31(4):690-8.
43. Schoffski P, **Garcia JA**, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinar F. A Phase 2 Study of the Efficacy and Safety of AMG 102 in Patients with Metastatic Renal Cell Carcinoma. *BJU Int*. 2011 Sep;108(5):679-86.
44. Bose A, Taylor JL, Alber S, Watkins SC, **Garcia JA**, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. *Int J Cancer*. 2011 Nov 1;129(9):2158-70.
45. **Garcia JA**, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI. Phase I/II trial of subcutaneously administered IL-2, GM-CSF and IFN- α 2b in patients with metastatic renal cell carcinoma (mRCC). *BJU Int*. 2012 Jan;109(1):63-9.
46. Shepard DR, Cooney MM, Elson P, Dreicer R, Rini BI, **Garcia JA**. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. *Invest New Drugs*. 2012 Feb;30(1):364-7.
47. Kim JJ, Vaziri S, Rini BI, Elson P, **Garcia JA**, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. *Cancer*. 2012 Apr 1;118(7):1946-54.

48. Rini BI, **Garcia J**, Elson P, Wood L, Shah S, Stephenson A, Salem M, Gong M, Fergany A, Rabets J, Kaouk J, Krishnamurthi V, Klein E, Dreicer R, Campbell S. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. *J Urol*. 2012 May;187(5):1548-54.
49. Wahdan-Alaswad RS, Song K, Shola DTN, Magi-Galluzzi C, **Garcia JA**, Danielpour D. Smads 1 and 5 but not Smad8 are activated by Rapamycin and promote cytostatic/cell death responses in prostate cancer cells. *Mol Cancer Res*. 2012 Jun;10(6):821-33.
50. Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, **Garcia JA**, Escudier BJ, Rini BI. Cessation of VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients: feasibility and clinical outcome. *Cancer*. 2012 Jul 1;118(13):3277-82.
51. Triozzi PL, Achberger S, Aldrich W, **Garcia JA**, Dreicer R. Differential immunologic and microRNA effects of two dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor in patients with prostate cancer. *J Immunother*. 2012 Sep;35(7):587-94
52. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. (**Garcia JA**). Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*. 2013 Jan 10;368(2):138-48.
53. Dreicer R, **Garcia JA**, Rini B, Vogelzang N, Srinivas S, Somer B, Shi P, Kania M, Raghavan D. A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. *Invest New Drugs*. 2013 Aug;31(4):1044-50.
54. **Garcia JA**, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. *Urol Oncol*. 2014 Jan;32(1):33.e11-7
55. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP. Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group (**Garcia JA**). Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. *Urology*. 2014 Mar;83(3):664-9.
56. Salem ME, Shah SN, Elson P, **Garcia JA**, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI. Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. *Clin Genitourin Cancer*. 2014 Apr;12(2):117-23
57. Seastone DJ, Elson P, **Garcia JA**, Chao ST, Sugh JH, Angelov L, Rini BI. Clinical Outcome of Stereotactic Radiosurgery for Central Nervous System Metastases from Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2014 Apr;12(2):111-6.
58. Najjar YG, Mittal K, Elson P, Wood L, **Garcia JA**, Dreicer R, Rini BI. A 2 weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. *Eur J Cancer*. 2014 Apr;50(6):1084-9
59. **Garcia JA**, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. A Phase II, Single-Arm Study of Ramucirumab in Patients with Metastatic Renal Cell Carcinoma with Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. *Cancer*. 2014 Jun 1;120(11):1647-55.
60. Fizazi K, Massard C, Bono P, Jone R, Kataja V, James N, **Garcia JA**, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. *Lancet Oncol*. 2014 Aug;15(9):975-85.
61. Rini BI, Redman B, **Garcia JA**, Burris HA 3rd, Li S, Fandi A, Beck R, Jungnelius U, Infante JR. A Phase 1/2 Study of Lenalidomide in Combination with Sunitinib in Patients with Advanced Renal Cell Carcinoma. *Ann Oncol*. 2014 Sep;25(9):1794-9.
62. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. (**Garcia JA**). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*. 2015 Feb;16(2):152-60
63. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W,

- Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, **Garcia JA**, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur Urol*. 2015 Feb;67(2):241-9.
64. Li Z, Bishop A, Alyamani M, **Garcia JA**, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N. Conversion of abiraterone to D4A drives antitumor activity in castration-resistant prostate cancer. *Nature*. 2015 Jul 16;523(7560):347-51
65. Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, **Garcia J**, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. *J Urol*. 2015 Aug;194(2):297-303
66. Sweeney CJ, Chen YH, Carducci M, Liu G, Eisenberger M, Wong YN, Hahn NM, Kohli M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, **Garcia JA**, DiPaola R. Chemohormonal Therapy and Overall Survival in Metastatic Hormone Sensitive Prostate Cancer. *N Engl J Med*. 2015 Aug 20;373(8):737-46.
67. **Garcia JA**, Sweeney C; Trial Investigators. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2016 Jan 21;374(3):287.
68. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, **Garcia JA**, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncol*. 2016 Mar;17(3):378-88.
69. Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, **Garcia JA**, Rini BI, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. *BMC Cancer*. 2016 Mar 29;16:254.
70. Ornstein MC, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, **Garcia JA**, Rini BI. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017 Apr;15(2):e275-e280.
71. Ornstein MC, **Garcia JA**, Sharifi N. Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition. *Transl Androl Urol*. 2016 Aug;5(4):616-9.
72. Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, **Garcia JA**, Plimack ER. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. *Lancet Oncol*. 2016 Sep;17(9):1317-24
73. Naik M, Reddy CA, Stephans KL, Ciezki JP, **Garcia J**, Grivas P, Stephenson AJ, Klein EA, Tendulkar RD. Post-treatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. *Int J Radiat Oncol Biol Phys*. 2016 Nov 1;96(3):617-23
74. Miller JA, Balagamwala EH, Angelov L, Suh JH, Rini B, **Garcia JA**, Ahluwalia M, Chao ST. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. *J Neurosurg Spine*. 2016 Dec;25(6):766-774.
75. Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, **Garcia JA**, Rini BI. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2017 Jun 1;35(16):1764-1769.
76. Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin ME, **Garcia JA**, Courtney K, Klein EA, Sharifi N. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. *eLife* 2017;6:e20183.
77. Zargar H, Almassi N, Kovac E, Ercole C, Remer E, Rini B, Stephenson A, **Garcia JA**, Grivas P. Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. *Bladder Cancer*. 2017 Jan 27;3(1):57-63.
78. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, **Garcia J**, Rini B, Grivas P. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. *Ann Oncol*. 2017 Oct 1;28(10):2458-2463
79. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, **Garcia JA**, Rini B, Grivas P. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. *Clin Genitourin Cancer*. 2018 Apr;16(2):e437-e442

80. Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B. Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. *Clin Genitourin Cancer*. 2018 Jun;16(3):e663-e667
81. Koshkin VS, Barata P, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pall SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, **Garcia JA**, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. *J Immunother Cancer*. 2018 Jan 29;6(1):9
82. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger MA, Kohli K, Plimack ER, Vogelzang NJ, Picus P, Cooney MV, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-term Survival Analysis of the Randomized Phase III E3805: CHAARTED Trial. *J Clin Oncol*. 2018 Jan 31;JCO2017753657. doi: 10.1200/JCO.2017.75.3657. [Epub ahead of print]
83. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, **Garcia JA**, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel. *J Clin Oncol*. 2018 Feb 1;36(4):376-382.
84. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, **Garcia JA**, Hussain MH, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of metastatic castrate naïve prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. *Eur Urol*. 2018 Feb 20. pii: S0302-2838(18)30102-7. [Epub ahead of print]
85. Emamekhoo H, Dhillon P, Gopalakrishnan D, Elson P, Stephenson A, Magi-Galluzzi C, McKenney J, Harper H, Haber GP, Kaouk J, Lee B, Fergany A, Berglund R, Gong M, Stein R, Krishnamurthi V, Gilligan T, Ornstein M, Rini B, **Garcia J**, Grivas P. Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2018 Feb 6. [Epub ahead of print]
86. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, **Garcia JA**, Rini BI, Grivas P. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. *Clin Genitourin Cancer*. 2018 Feb 22. [Epub ahead of print]
87. Barata P, Cooney M, Wright J, Dreicer R, **Garcia JA**. A Phase 2 Study of OSI-906 (Linsitinib, an Insulin-Like Growth Factor Receptor-1 Inhibitor) in Patients with Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC). *Invest New Drugs*. 2018 Feb 23. doi: 10.1007/s10637-018-0574-0. [Epub ahead of print]
88. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. 2018 Feb;23(2):193-202.
89. Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, **Garcia JA**, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of life (QOL) during treatment with chemohormonal therapy: Analysis of E3805 Chemohormonal androgen ablation randomized trial in prostate cancer (CHAARTED). *J Clin Oncol*. 2018 Mar 9;JCO2017753335. doi: 10.1200/JCO.2017.75.3335. [Epub ahead of print]
90. Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, **Garcia JA**, Grivas P. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. *Urol Oncol*. 2018 Mar 29 [Epub ahead of print]
91. Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, **Garcia JA**, Powles T, Rini BI. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. *Br J Cancer*. 2018 Jul;119(2):160-163.
92. Barata PC, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini B, Gilligan T, Kyriakopoulos C and **Garcia JA**. Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo-Hormonal Therapy. *Prostate*. 2018 Jun 7. doi: 10.1002/pros.23663. [Epub ahead of print]
93. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, **Garcia JA**, Grivas P. Atezolizumab in Metastatic Urothelial

- Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. *Target Oncol.* 2018 Jun;13(3):353-361
94. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay SU, Tyler A, Berk M, Hu B, Hwang TH, Figg W, Peer C, Chien C, Koshkin V, Mendiratta P, Grivas P, Rini B, **Garcia J**, Auchus R and Sharifi N. HSD3B1(1245A>C) Variant Regulates Dueling Abiraterone Metabolite Effects in Prostate Cancer. *J Clin Invest.* 2018 Jun 25. pii: 98319. doi: 10.1172/JCI98319. [Epub ahead of print]
 95. Barata PC, Mendiratta P, Heald B, Klek S, Grivas P, Sohal DPS, **Garcia JA**. Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study. *Target Oncol.* 2018 Jul 4. doi: 10.1007/s11523-018-0576-z. [Epub ahead of print]
 96. Autio K, Dreicer R, Anderson J, **Garcia J**, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber N, Summa JM, Youssoufian H, Morris MJ, Scher HI. BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen (PSMA) in chemotherapy-naïve metastatic castration-resistant prostate cancer: A phase 2 trial. *JAMA Oncol.* 2018 Jul 5. doi: 10.1001/jamaoncol.2018.2168. [Epub ahead of print]
 97. Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, **Garcia JA**. The Impact of Switching Systemic Treatment after Stereotactic Radiosurgery (SRS) For OligoProgressive, Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.
 98. Monk P, Liu G, Stadler W, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N and **Garcia JA**. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). *Invest New Drugs.* 2018 Aug 7. doi: 10.1007/s10637-018-0630-9. [Epub ahead of print]
 99. Emamekhoo H, Barat PC, Edwin NC, Woo KM, Grivas P, and **Garcia JA**. Evaluation of Response to Enzalutamide Consecutively after Abiraterone Acetate/Prednisone Failure in Patients with Metastatic Castration Resistant Prostate Cancer. *Clin Genitourin Cancer.* 2018 Aug 17. pii: S1558-7673(18)30433-6. doi: 10.1016/j.clgc.2018.08.002. [Epub ahead of print]
 100. Almassi N, Gao T, Byron L, Stein R, Haber GP, Ornstein MC, Rini BI, Gilligan T, Garcia JA, Stephenson, A, Grivas P. Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract Urothelial carcinoma undergoing extirpative surgery. *Clin Genitourin Cancer.* 2018 Aug 22. pii: S1558-7673(18)30376-8. doi: 10.1016/j.clgc.2018.08.003. [Epub ahead of print]
 101. Barata PC, Cooney M, Mendiratta P, Tyler A, Dreicer R and **Garcia JA**. Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): Results of an open-label phase II study. *Invest New Drugs.* 2018 Sep 6. doi: 10.1007/s10637-018-0660-3. [Epub ahead of print]
 102. Zahoor H, Pavicic PG, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein, Garcia J and Rini BI. Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. *Medicine (Baltimore).* 2018 Sep;97(37):e12344
 103. Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC and Grivas P. Immunological correlates of response to immune checkpoint inhibitors in metastatic Urothelial Carcinoma. *Target Oncol.* 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.
 104. Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, **Garcia JA**, Rini BI. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. *Urol Oncol.* 2018 Oct;36(10):470.e19-470.e29.
 105. Koshkin VS, **Garcia JA**, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. *Clin Cancer Res.* 2018 Oct 16. doi: 10.1158/1078-0432.CCR-18-1278. [Epub ahead of print]
 106. Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan T, Grivas P, Ornstein MC, Garcia JA, Rini BI. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with Nivolumab. *J Immunother Cancer.* 2018 Oct 17;6(1):107
 107. Barata PC, Cooney M, Mendiratta P, Gupta R, Dreicer R, **Garcia JA**. Phase I/II study evaluating the safety and clinical efficacy of tamsulosin and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. *Invest New Drugs.* 2019 Apr;37(2):331-337

108. Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, Murphy ES, Suh JH, Barnett GH, Yu JS, Vogelbaum MA, Rini B, **Garcia J**, Stevens GH, Angelov L and Chao ST. Overall Survival and the Response to Radiation and Targeted Therapies among Patients with Renal Cell Carcinoma Brain Metastases. *J Neurosurg.* 2019 Jan 18:1-9. doi: 10.3171/2018.8.JNS182100. [Epub ahead of print]
109. Almassi N, Glass KE, Lonzer JL, Urbanek DS, Grivas P, Rini B, **Garcia J**, Stephenson AJ, Klein EA and Krishnamurthi V. Identifying institutional causes of delay to radical cystectomy among patients with high-risk bladder cancer managed at a tertiary referral center using process map analysis. *Urology Practice* 2018
110. Slovin S , Hussain S , Saad F, **Garcia JA**, Picus J , Ferraldeschi R , Crespo M , Flohr PR , Riisnaes R , Lin C , Keer H , Oganessian A , Workman P. Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. *Clin Cancer Res.* 2019 Aug 1;25(15):4624-4633.
111. Barata PC, Magi-Galluzzi C, Gupta R, Dreicer R, Klein EA, **Garcia JA**. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. *Clin Genitourin Cancer.* 2019 May 25. pii: S1558-7673(19)30159-4. doi: 10.1016/j.clgc.2019.05.021. [Epub ahead of print]
112. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, **Garcia JA**. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. *Invest New Drugs.* 2019 Jun;37(3):559-566.
113. Zahoor H, Mir MC, Barata PC, Stephenson AJ, Campbell SC, Fergany A, Dreicer R, **Garcia JA**. Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. *Invest New Drugs.* 2019 Jun 24. doi: 10.1007/s10637-018-00716-w. [Epub ahead of print]
114. Ornstein MC, Wood LS, Hobbs BP, Allman KD, Martin A, Bevan M, Gilligan TD, **Garcia JA**, Rini BI. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. *J Immunother Cancer.* 2019 May 16;7(1):127.
115. Ornstein MC, Calabrese C, Wood LS, Kirchner E, Profusek P, Allman KD, Martin A, Kontzias A, Grivas P, **Garcia JA**, Calabrese LH, Rini BI. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. *Clin Genitourin Cancer.* 2019 Jun;17(3):177-182
116. Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, **Garcia JA**, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. *Lancet Oncol.* 2019 Oct;20(10):1386-1394.
117. Gupta R, Ornstein MC, Li H, Allman KD, Wood LS, Gilligan T, Garcia JA, Merveldt DV, Hammers HJ, Rini BI. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2019 Dec 5:S1558-7673(19)30363-5.
118. Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, **Garcia JA**, Klein EA, Sharifi N. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. *Ann Oncol.* 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11.
119. Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, **Garcia JA**, Carducci MA, DiPaola RS, Sharifi N. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. *JAMA Oncol.* 2020 Feb 13:e196496. doi: 10.1001/jamaoncol.2019.6496. [Epub ahead of print]
120. Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, **Garcia JA**, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. *Mol Ther.* 2020 Mar 3. pii: S1525-0016(20)30134-9. doi: 10.1016/j.ymthe.2020.02.018. [Epub ahead of print]
121. Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, **Garcia JA**, Klein EA, Sharifi N. Deep androgen receptor suppression in **prostate** cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. *Ann Oncol.* 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11.
122. Fallah J, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Dann P, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan T, **Garcia JA**, Rini B, Ornstein MC, Grivas P. Myeloid-Derived Suppressor Cells in Non-metastatic Urothelial Carcinoma of Bladder Is

- Associated With Pathologic Complete Response and Overall Survival. Clin Genitourin Cancer. 2020 Mar 19:S1558-7673(20)30053-7
123. Sheng IY, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, **Rini BI**, Garcia JA, Grivas P, Ornstein MC. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. Target Oncol. 2020 Apr;15(2):211-220
 124. Gupta R, Sheng IY, Barata PC, **Garcia JA**. Non-metastatic castration-resistant prostate cancer: current status and future directions. Expert Rev Anticancer Ther. 2020 Jun;20(6):513-522
 125. Sheng IY, Chen, YW, Barata P, Gilligan TD, Ornstein MO, Rini BI, Garcia JA. Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. Clin Genitourin Cancer. 2020 Jul 11:S1558-7673(20)30145-2.
 126. Bryce AH, Chen YH, Liu G, Carducci MA, Jarrard DF, **Garcia JA**, Dreicer R, Hussain M, Eisenberger MA, Plimack ER, Volgelzang NJ, DiPaola RS, Harshman LC, Sweeney CJ. Patterns of Cancer Progression of Metastatic Hormone Sensitive Prostate Cancer in the E3805 CHARTED trial. Eur Urol Oncol. 2020 Aug 14:S2588-9311(20)30092-4.
 127. Sheng IY, Barata P, Gilligan TD, Ornstein MO, Rini BI, **Garcia JA**. Identifying Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Target Oncol. 2020 Aug;15(4):477-483.
 128. Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, **Garcia JA**, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8 + T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Mol Ther. 2020 May 6;28(5):1238-1250.
 129. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilan MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium – (**Garcia JA**). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28.
 130. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org; COVID-19 and Cancer Consortium (**Garcia JA**). A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell. 2020 Oct 29:S1535-6108(20)30553-5
 131. Armstrong AJ, Nixon AB, Carmack A, Eisen T, Stadler WM, Jones RJ, **Garcia JA**, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, and Halabi S. Angiokines associated with targeted therapy outcomes in patients with non-clear cell renal cell carcinoma.

Invited, Peer-Reviewed

1. **Garcia J**. Prostate Cancer: Recent Developments in Prevention, Diagnosis and Treatment. New Urology: Prostate Cancer 1(3):9-14, 2004.
2. **Garcia J**. Prostate Cancer: Recent Developments in Prevention, Diagnosis and Treatment. New Urology: Prostate Cancer 1(3):9-14, 2004.
3. **Garcia J**, Small EJ. Treatment for Hormone Refractory Prostate Cancer. Contemporary Urology. 22:4, 2004.
4. **Garcia JA** and Dreicer R. Adjuvant and Neoadjuvant chemotherapy for bladder cancer; Management and Controversies. Nature Clinical Practice Urology 2:(1);32-37, 2005.

5. **García JA**, and Rini B. Advances in the treatment of Renal Cell Carcinoma with Angiogenesis - targeted therapy. *Angiogenesis in Oncology* 1(4):3-6, 2005.
6. Takkar S, Choeri T, **García JA**. Endothelin Receptor Antagonists: Rationale, Clinical Development, and Role in Prostate Cancer Therapeutics. *Curr Oncol Rep* 8(2):108-13, 2006.
7. **García JA** and Dreicer R. Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies. *J Clin Oncol* 24(35):5545-5551, 2006.
8. **García JA** and Rini B. Recent Progress in the Management of Advanced Renal Cell Carcinoma. *CA Cancer J Clin* 57(2):112-25, 2007.
9. **García JA**. Improving Outcome in High-Risk Bladder cancer: Neoadjuvant and Adjuvant Chemotherapy. 2008 ASCO GU Symposium Educational Book; 63-65, 2008.
10. **García JA** and Danielpour D. Rationale for mTOR inhibition in Urologic malignancies. *Mol Cancer Ther*. 7(6):1347-54, 2008.
11. Heng D, **García JA**. Current Approach for High-risk TCC of the Bladder: Rationale of Neoadjuvant and Adjuvant Systemic Chemotherapy. *Oncol Rev* 2:4-8, 2008.
12. **García JA**, Cowey CL, Godley PA. Advanced Renal Cell Carcinoma. *Current Opinion in Oncology* 21(3):266-71, 2009.
13. Shepard D, **García JA**. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. *Expert Rev Anticancer Ther* 9(6):795-805, 2009.
14. Schwandt A, **García JA**. Complications of Androgen Deprivation Therapy in Prostate Cancer. *Current Opinion in Urology* 19(3):322-6, 2009.
15. Salem M, **García JA**. Abiraterone Acetate, A novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer (CRPC). *Curr Oncol Rep*. 2011 Jan 18. [Epub ahead of print]
16. **García JA**. Sipuleucel-T in Patients with Metastatic Castrate Resistant Prostate Cancer (CRPC): An Insight for Oncologists. *Therapeutic Advances in Medical Oncology*. March 2011 3: 101-108
17. **García JA**, Dreicer R. Immunotherapy in Castration-Resistant Prostate Cancer: Integrating Sipuleucel-T in to Our Current Treatment Paradigm. *Oncology (Williston Park)*. 2011 Mar;25(3):242-9.
18. Husseinzadeh HD, **García JA**. Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma. *Curr Clin Pharmacol*. 2011 Aug;6(3):214-21.
19. **García JA**, Rini BI. Castration-resistant prostate-cancer: many treatments, many options, many challenges head. *Cancer*. 2012 May 15;118(10):2583-93.
20. Haddad H, **García JA**. Novel Agents for the Management of Castration-resistant Prostate Cancer (CRPC). *Curr Opin Urol*. 2012 May;22(3):175-82.
21. Sadeghi S, **García JA**. Overcoming VEGF Resistance in Renal Cancer: Biologic and Therapeutic Implications. *Clinical Investigation* 2012;2:615-621.
22. Sadeghi S, **García JA**. Current Status of Targeted Therapy in Metastatic Transitional Cell Carcinoma of the Bladder. *Semin Oncol*. 2012 Oct;39(5):608-14.
23. Zhu H, **García JA**. Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor. *Curr Oncol Rep*. 2013 Apr;15(2):105-12.
24. Khurana KK, **García JA**, Tendulkar RD, Stephenson AJ. Multidisciplinary management of patients with localized bladder cancer. *Surg Oncol Clin N Am*. 2013 Apr;22(2):357-73.
25. Linenhan WM, Srinivasan R, **García JA**. Non-Clear Cell Renal Cancer: Disease-Based Management and Opportunities for Targeted Therapeutic Approaches. *S* 2013 Aug;40(4):511-20.
26. Chaturvedi S and **García JA**. Novel Agents in the Management of Castration-resistant Prostate Cancer. *J Carcinog*. 2014 Mar 5;13:5.
27. González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, **García JA**, Suárez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. *Crit Rev Oncol Hematol*. 2017 May;113:171-190.
28. Barata PC, Ornstein MC, **García JA**. The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. *J Kidney Cancer VHL*. 2017 May 11;4(2):10-18
29. Ornstein MC, **García JA**. Toxicity of Checkpoint inhibition in Advanced RCC: A systematic review. *Kidney Cancer* 2017 (In Press)
30. Gul A, **García JA**, Barata PC. Treatment of non-metastatic castration-resistant prostate cancer: Focus on Apalutamide. *Cancer Manag Res*. 2019 Aug 1;11:7253-7262.
31. Brown Jason R, Krane S, **García JA** and Barata PC. Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma. *Therapeutic Advances in Urology* 2020 (In Press)

Book Chapters

1. Small E, **Garcia J**, Torti FM. Testicular Carcinoma in: Clinical Oncology. Abeloff, Armitage, Litcher and Niederhuber, eds. April, 2004.
2. **Garcia J**, Rini B. Testicular Carcinoma: In Holland-Frei manual of Cancer Medicine. Brown, Rini, Connell, and Posner, eds. 2005.
3. **Garcia J**, Rini B. Bladder Carcinoma: In Holland-Frei manual of Cancer Medicine. Brown, Rini, Connell, and Posner, eds. 2005.
4. Rini BI, **Garcia JA**. Biochemical recurrence of prostate cancer. In: Gulley JL, Dahut WL, Moul JW, Sandler HM, eds. Prostate Cancer: A Clinical Guide. Philadelphia, Penn: Lippincott, Williams & Wilkins; 2007.
5. Raghavan D, Stephenson A, **Garcia JA**. Bladder, Renal and Testicular Cancer in: American College of Physicians - Medicine 2007.
6. **Garcia JA**, and Dreicer R. Neoplasms of the Renal Pelvis and Ureter in: Clinical Management of Renal Tumors. Bukowski, Ronald M.; Novick, Andrew (Eds.) 2008, XVIII, 665 p. 174 illus., Hardcover ISBN: 978-1-58829-251-3
7. **Garcia JA**, and Ganapathi R. Proteasome / NFkB – Relevance in RCC in: Molecular Targets and Clinical Applications, Second Edition. Bukowski, Ronald M.; Figlin, Robert A.; Motzer, Robert (Eds.) 2nd ed., 2009, XVIII, 506 p. ISBN: 978-1-58829-737-2.
8. **Garcia JA** and Rini BI. Targeted VEGF Therapy in the Management of Advanced Renal Cell Carcinoma in Genitourinary Oncology, 4th edition. NJ. Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ, Rini BI, Bochner BH, Sheinfeld J. (Eds.) Philadelphia; Lippincott Williams & Wilkins 2011.
9. **Garcia JA**, Shepard D, Dreicer R. Neoadjuvant and Adjuvant Systemic Chemotherapy for High-risk Transitional Cell carcinoma of the Bladder in The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management. Hansel DE, McKenney JK, Stephenson AJ, Chang SS. (Eds). Springer Science 2012
10. Hurwitz M, Spiess PE, **Garcia JA**, Pisters LL. Urothelial and Kidney cancers in: cancer Management: A multidisciplinary approach, 14th edition. Richard Pazdur, Kevin Camphausen, Bill Hoskins and Larry Wagman. CMP Medica 2012.
11. **Garcia JA** and Dreicer R. Current Management of Castration-Resistant Prostate cancer (CRPC). Management of Prostate Cancer 3rd. ed. 2012.
12. Rini BI, **Garcia JA**, Gilligan T, Dreicer R. GU Cancers. Andreoli and Carpenter's Cecil Essentials of Medicine 9th ed. (In press)
13. Michener C and **Garcia JA**. Gynecologic, Prostate and Testicular Cancer. CCF intensive Review of Internal Medicine 6th ed. 2013
14. Hurwitz M, Spiess PE, Garcia JA, Pisters LL. Urothelial and Kidney cancers in: cancer Management: A multidisciplinary approach, 16th edition. Richard Pazdur, Kevin Camphausen, Bill Hoskins and Larry Wagman. CMP Medica 2014.
15. **Garcia JA**, Finke J, Storkus W. Vaccines in RCC: Clinical and Biological Relevance. Renal Cell Carcinoma: Molecular Targets & Clinical Applications. 3rd ed. 2013
16. **Garcia JA** and Dreicer R. Defining Clinical Endpoints in Castration-resistant prostate cancer. Management of Castration Resistant Prostate Cancer, edited by Dr. Saad and Dr. Eisenberger; Springer Science and Business Media 2014
17. Dreicer R, Ornstein MC, Mittal K, Reynolds J, Klink J, Przybycin C, **Garcia JA**. Adrenal cortical carcinoma and Pheochromocytoma. American Cancer Society Clinical Oncology Textbook 2019

Editorials

1. Mendiratta P and **Garcia JA**. Relapsing Prostate Cancer; Castrate or Cure. : International Journal of Radiation Oncology, Biology, Physics 2018.

Abstracts

1. Exley M, Furman M, **Garcia J**, Balk S, Porcelli S. Regulation of CD161-Reactive Human Immunoregulatory CD161+ T cell effector functions. Abstract. Presented at the New England Immunology Conference, Woods Hole, MA, 1997.

2. **Garcia J**, Exley M, Balk S. CD1d expression by human thymocytes. (Abstract) Presented at the New England Immunology Conference. Woods Hole, MA, 1997.
3. **Garcia J**, Weinberg V, Rini B, Rosenberg J, Ryan C, Small E. Abstract. Prior Estrogen therapy as a predictor of response to subsequent estramustine-based therapy in Androgen-Independent prostate cancer patients. ASCO 2004, Abstract #4251. Orlando, FL.
4. Randall M, Rini B, Ryan C, Rosenberg J, **Garcia J**, Bublely G, Small E. Abstract. The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a Phase II trial. ASCO 2004, Abstract #4617. Orlando, FL.
5. Salas R, Shaheen PE, Rini BI, **Garcia J**, Dreicer R, Wood L, Bukowski RM. Thyroid Function Test (TFTs) Abnormalities associated with SU11248 treatment in patients with Metastatic renal cell carcinoma of clear cell histology. Abstract. 4th Annual Kidney Cancer Symposium. Chicago, IL, 2005.
6. Ciezki JP, Reddy CA, **Garcia J**, PSA Kinetics Following Prostate Brachytherapy; The PSA Bounce Phenomenon and its implications in PSA Doubling time. American Society for Therapeutic Radiology and Oncology (ASTRO), Abstract #2150. Denver, CO, 2005.
7. Thakkar S, **Garcia J**, Rothaermel J, et al. A phase II trial of Gemcitabine and Docetaxel in Hormone Refractory Prostate Cancer. ASCO Prostate Cancer Symposium. Abstract #232. San Francisco, CA, 2006.
8. **Garcia J**, Magi-Galluzzi C, Rothaermel J, et al. Neoadjuvant GM-CSF and Thalidomide in men with high-risk prostate cancer undergoing radical prostatectomy. ASCO Prostate Cancer Symposium. Abstract #252. San Francisco, CA, 2006.
9. Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemeč C, **Garcia J**, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. ASCO 2006, Abstract #4597. Orlando, FL.
10. Choueiri TK, Dreicer R, Rini BI, Elson P, **Garcia J**, et al. Phase II study of lenalidomide in patients (pts) with metastatic renal cell carcinoma (MRCC). ASCO 2006, Abstract #4539. Orlando, FL.
11. Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P, Shaheen P, **Garcia J**, et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. ASCO 2006, Abstract #2526. Orlando, FL.
12. Thakkar S, Hutson T, J. **Garcia J**, et al. A phase II trial of Gemcitabine and Docetaxel in hormone-refractory metastatic prostate cancer. ASCO 2006, Abstract #14501. Orlando, FL.
13. Shaheen PE, Tamaskar I, Salas R, Rini BI, **Garcia J**, Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. ASCO 2006, Abstract #4605. Orlando, FL.
14. **Garcia JA**, Triozzi P, Smith S, et al. Phase I/II Study of Lenalidomide (Revlimid®) and GM-CSF (Leukine®) in Hormone Refractory Prostate Cancer (HRPC). ASCO Prostate Cancer Symposium 2007. Abstract # 229. Orlando, FL.
15. George S, Richmond A, Elson P, Jin T, Wood L, **Garcia JA**, et al. WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib. ASCO 2007. Abstract # 5043. Chicago, IL.
16. Golshayan A, Choueiri TK, Elson P, **Garcia JA**, et al. Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. ASCO 2007. Abstract # 5046. Chicago, IL.
17. Unnithan JS, Choueiri TK, **Garcia JA**, et al. Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. ASCO 2007. Abstract # 5047. Chicago, IL.
18. Tamaskar IR, Unnithan JS, **Garcia JA**, et al. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with Sorafenib. ASCO 2007. Abstract # 5048. Chicago, IL
19. **Garcia JA**, Rini BI, Triozzi P, et al. A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). ASCO 2007. Abstract # 5103. Chicago, IL
20. Dreicer R, **Garcia JA**, Smith S, et al. Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC). ASCO 2007. Abstract 15515. Chicago, IL
21. Heng DY, Rini BI, **Garcia JA**, et al. Durable complete responses and near complete responses o sunitinib in metastatic renal cell carcinoma. ASCO 2007. Abstract 15514. Chicago, IL.
22. Cooney MM, **Garcia JA**, Brell J, et al. A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. ASCO 2007. Abstract 15532. Chicago, IL.

23. Khasawneh MF, Unnithan JS, Choueiri TK, Rini BI, Dreicer R, **Garcia JA**, et al. Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's). ASCO 2007. Abstract 15583. Chicago, IL.
24. George S, Rini BI, **Garcia JA**, et al. Dose escalation of sorafenib after disease progression on standard dose in metastatic renal cell carcinoma (RCC). The sixth international kidney cancer symposium. Chicago, IL.
25. Golshayan AR, George S, Mekhail T, Choueiri TK, Elson P, Wood L, **Garcia JA**, et al. Metastatic renal cell carcinoma (RCC) with Sarcomatoid differentiation treated with VEGF-targeted therapy. Sixth international kidney cancer symposium. Chicago, IL.
26. **Garcia JA**, Cooney MM, Elson P, et al. Clinical activity of Ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial. ASCO GU symposium 2008. San Francisco, CA.
27. mTOR pathway in prostate cancer: Immunohistochemical expression on tissue microarrays. **Garcia JA**, Reuther AM, Stephenson AJ, et al. ASCO GU symposium 2008. San Francisco, CA.
28. Shepard DR, Dreicer R, **Garcia JA**, et al. Phase II trial of neoadjuvant albumin-bound paclitaxel in high-risk patients with prostate cancer undergoing radical prostatectomy. ASCO GU symposium 2008. San Francisco, CA.
29. Rini BI, Hutson TE, Elson PE, **Garcia JA**, et al. A prospective trial of Sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. ASCO GU symposium 2008. San Francisco, CA.
30. Golshayan AR, George S, Heng D, Elson P, Wood L, Mekhail T, **Garcia JA**, et al. Metastatic renal cell carcinoma with Sarcomatoid component treated with VEGF-targeted therapy. ASCO GU symposium 2008. San Francisco, CA.
31. **Garcia JA**, Cooney MM, Mekhail T, et al. Sunitinib and bevacizumab in advanced solid tumors: preliminary results of a phase I trial. ASCO GU symposium 2008. San Francisco, CA.
32. Wood L, Bukowski RM, Dreicer R, Elson P, **Garcia JA**, et al. Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy. ASCO GU symposium 2008. San Francisco, CA.
33. Heng D, Neyman J, Suh J, Elson P, **Garcia JA**, et al. Prospective study of stereotactic radiosurgery (SRS) for pain and tumor control for patients with renal cell carcinoma and spinal metastases. ASCO GU symposium 2008. San Francisco, CA.
34. George S, **Garcia JA**, Golshayan AR, et al. Dose escalation of sorafenib in metastatic renal cell carcinoma patients. ASCO GU symposium 2008. San Francisco, CA.
35. Golshayan AR, George S, Elson P, Wood L, **Garcia JA**, et al. VEGF-targeted therapy for metastatic renal cell carcinoma with renal insufficiency. ASCO GU symposium 2008. San Francisco, CA.
36. Tamaskar IR, Rini BI, Mekhail T, Triozzi P, Elson P, Nemec C, Bukowski RM, **Garcia JA**. A Phase II trial of low-dose IL-2 and bevacizumab for patients with metastatic renal cell carcinoma. ASCO GU symposium 2008. San Francisco, CA.
37. Vakkalanka BK, Elson P, Wood L, **Garcia JA**, et al. Long-term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma. ASCO GU symposium 2008. San Francisco, CA.
38. Heng D, Chi KN, Murray N, Jin T, Rini BI, **Garcia JA**, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. ASCO GU symposium 2008. San Francisco, CA.
39. Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. Cooney MM. **Garcia JA**, Elson P, et al. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3530)
40. **Garcia JA**, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5143)
41. Shepard DR, Rini BI, **Garcia JA**, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5123)
42. Salas RN, Ireland JL, Ko JS, Elson P, **Garcia JA**, et al. Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5099)

43. Vakkalanka BK, Elson P, Wood L, Dreicer R, **Garcia JA**, et al. Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 16045)
44. Golshayan AR, George S, Heng DY, Elson P, Wood L, **Garcia JA**, et al. Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5102)
45. Faber PW, Vaziri SA, Wood L, Nemecek C, Elson P, **Garcia JA**, et al. Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5009)
46. Wood L, Bukowski RM, Dreicer R, Elson P, **Garcia JA**, et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 16067)
47. Dreicer R, Kania M, Musib L, Rini B, **Garcia JA**, et al. A placebo-controlled phase II study of enzastaurin combined with docetaxel (D) and prednisone (P), followed by enzastaurin maintenance in castrate, metastatic prostate cancer: Safety lead-in results. Abstract 178, ASCO GU 2009.
48. Shepard DR, Weil A, **Garcia J**, et al. Docetaxel efficacy/toxicity in patients aged 70-85 years with metastatic prostate cancer. Abstract 213, ASCO GU 2009.
49. Weight C, **Garcia J**, Hansel D, et al. Lack of pathological down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series. Abstract 272, ASCO GU 2009.
50. Barbastefano J, **Garcia JA**, Elson P, et al. Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. Abstract , ASCO GU 2009.
51. Rini BI, **Garcia J**, elson P, et al. Neoadjuvant sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). Abstract 288, ASCO GU 2009.
52. Schwandt A, Wood L, Bukowski RM, Elson P, **Garcia JA**, et al. Temsirolimus in metastatic renal cell carcinoma: Safety and efficacy in patients previously treated with VEGF-targeted therapy. Abstract 293, ASCO GU 2009.
53. Golshayan AR, Elson P, Wood L, **Garcia JA**, et al. Impact of tumor volume on outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Abstract 309, ASCO GU 2009.
54. Schwandt A, **Garcia JA**, Elson P, et al. A translational phase II trial of celecoxib plus interferon-alpha (IFN- α 2b) in metastatic renal cell carcinoma (RCC) patients (pts) with 3+ COX-2 tumor immunostaining. J Clin Oncol 27:15s, 2009 (suppl; abstr 5116)
55. Wood L, **Garcia JA**, Elson P, et al. Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5096)
56. Barbastefano J, **Garcia JA**, Elson P, et al. Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. J Clin Oncol 27:15s, 2009 (suppl; abstr 5095)
57. Fairouz K, **Garcia JA**, Stadler W, et al. Efficacy and Safety of AMG 102 in Patients with advanced Renal Cell Carcinoma (RCC). ESMO 2009.
58. **Garcia JA**, Hudes G, Choueiri TK, et al. Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12-0605/NCT00515697). ESMO 2009.
59. Shepard DR, Ireland J, Stephenson A, Campbell S, Gong M, Elson P, Dreicer R, Raghavan D, Finke J, **Garcia JA**. Effects of sunitinib on immune dysfunction in patients with transitional cell carcinoma (TCC) of the bladder. ASCO GU 2010, abstract 295.
60. Varella L, Karam JA, Wood CG, **Garcia JA**, et al. Metastasectomy following targeted therapy in patients with renal cell carcinoma (RCC). ASCO GU2010, abstract 384.
61. **Garcia JA**, Hudes G, Choueiri TK, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). ASCO GU2010, abstract 326.
62. Shepard DR, Weil A, **Garcia JA**, et al. Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. ASCO 2010. Abstract 4687.
63. Sadeghi S, Wood L, Black S, Dreicer R, **Garcia JA**, Rini BI. Cessation of VEGF-targeted Therapy in Metastatic RCC Patients: Feasibility and Clinical Outcome. 9th International KCA Symposium 2010.

64. **Garcia JA**, Stephenson AJ, Ireland J, et al. Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder. *J Clin Oncol* 29: 2011 (suppl 7; abstr 262)
65. Sadeghi S, Albiges L, Wood L, Black S, Gilligan T, Dreicer R, **Garcia JA**, et al. Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome. 2011 ASCO GU Meeting.
66. Mohammadi AM, Chao S, Rini BI, **Garcia JA**, et al. The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases. *J Clin Oncol* 30, 2012 (suppl 5; abstr 410)
67. Ali KB, Shah SN, Wood LS, **Garcia JA**, et al. Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. *J Clin Oncol* 30, 2012 (suppl 5; abstr 420)
68. Haddad H, Rini BI, Jonasch E, Tanir NM, Dreicer R, **Garcia JA**, et al. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 30, 2012 (suppl; abstr 4609)
69. **Garcia JA**, Elson P, Cooney MA, et al. Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of Temsirolimus (T) and Bevacizumab (B) in docetaxel-refractory metastatic CRPC. *J Clin Oncol* 30, 2012 (suppl; abstr e15208)
70. Shukla ME, Reddy CA, Stephans KL, Stephenson AJ, Klein EA, **Garcia JA**, et al. Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy. *J Clin Oncol* 30, 2012 (suppl 5; abstr 195)
71. Wood LS, Dreicer R, **Garcia JA**, et al. A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 30, 2012 (suppl; abstr TPS4684)
72. Yana George Najjar YG, Elson P, Wood LS, **Garcia JA**, et al. Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. *J Clin Oncol* 31, 2013 (suppl 6; abstr 406)
73. **Garcia JA**, Elson P, Cooney MA, et al. Phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). *J Clin Oncol* 31, 2013 (suppl 6; abstr 197)
74. Zhu H, Rayman PA, Elson P, Rapp S, **Garcia JA**, et al. Immune cell repertoire in patients with indolent metastatic renal cell carcinoma. *J Clin Oncol* 31, 2013 (suppl 6; abstr 429)
75. Fizazi K, Bono P, Jones R, Kataja V, James N, **Garcia J**, et al. An Open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC). ESMO 2013.
76. **Garcia JA**, Kataja VV, James ND, et al. Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 32, 2014 (suppl 4; abstr 102)
77. Zhao B, **Garcia JA**, Gilligan TD, et al. Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. *J Clin Oncol* 32, 2014 (suppl 4; abstr 99)
78. Mittal K, Derosa L, Albiges L, Wood LS, Elson P, Gilligan TD, **Garcia JA**, et al. Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 4521)
79. Alvarez AL, Plimack ER, Dreicer R, Gilligan TD, **Garcia JA**, et al. A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). *J Clin Oncol* 32:5s, 2014 (suppl; abstr 4522)
80. Massard C, Fizazi K, Bono P, Jones RH, Kataja VV, James ND, **Garcia JA**, et al. Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5079^)
81. Sweeney C, Chen YH, Carducci MA, Liu G, Frasier DJ, Eienberger MA, Wong YN, Hahn NM, Kohi M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shervin DH, Hussain M, **Garcia JA**, DiPaola RS. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr LBA2)
82. Ferraldeschi R, Slovin S, Hussain S, Saad F, **Garcia JA**, et al. A Phase 1/2 study of AT13387, a heat shock protein 90 (Hsp90) inhibitor in combination with abiraterone acetate (AA) and prednisone (P) in patients (pts) with castration-resistant prostate cancer (mCRPC) no longer responding to AA. ESMO 2014
83. Sweeney C, Chen YH, Carducci MA, Liu G, Frasier DJ, Eisenberger MA, Wong YN, Hahn NM, Kohi M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shervin DH, Hussain M, **Garcia JA**, DiPaola RS. E3805: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED). ESMO 2014

84. Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke J, **Garcia JA**, et al. Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 434)
85. Emamekhoo H, Gopalakrishnan D, Dhillon P, Al Taii H, Elson P, McKenney J, Magi-Galluzzi C, Harper HL, Zagar H, Rini BI, Stephenson AJ, Gong M, Fergany A, Haber G, Campbell S, Kaouk J, Berglung R, Stein R, **Garcia JA**, Grivas P. Evaluation of prognostic factors in upper tract urothelial carcinoma (UTUC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 372)
86. Autio KA, **Garcia JA**, Alva AS, et al. A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 233)
87. Ornstein MC, Stephenson AJ, Elson P, Tyler AJ, Profusek P, Grivas P, Rini BI, Kein E and **Garcia JA**. Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). *J Clin Oncol* 34, 2016 (suppl; abstr 5071)
88. Koshkin VS, Emamekhoo H, Elson P, McKenney J, Magi-Galluzzi, Schach K, Stephenson AJ, Rini BI, **Garcia JA**, Grivas P. Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC). *J Clin Oncol* 34, 2016 (suppl; abstr e16037)
89. Grivas P, Emamekhoo H, Elson P, McKenney J, Zagar H, Magi-Galluzzi C, Schach K, Brey ND, Stephenson AJ, McClanahan T, Yearley J, Blumenschein W, Annamalai K, Rini BI and **Garcia JA**. PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC). *J Clin Oncol* 34, 2016 (suppl; abstr e16023)
90. Ornstein MC, Diaz-Montero CM, Rayman PA, Elson P, Haywood S, Kim JS, Pavicic PG, Finke J, Rini BI, Stephenson AJ, Lamenza M, Dann P, Schach K, Devonshire S, Ko JS, Fergany AF, Ernstoff MS, Hoimes CJ, **Garcia JA**, Grivas P. Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 362)
91. Koshkin VS, Elson P, Magi-Galluzzi C, McKenney J, Streater Smith KS, Shadrach B, Emamekhoo H, Isse K, Saunders L, Kavalerchik E, Dylla S, Sheila Bheddah, Theiss N, Watson S, Stephenson AJ, Fergany AF, Rini BI, **Garcia JA**, Grivas P. Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). *J Clin Oncol* 35, 2017 (suppl 6S; abstract 382)
92. **Garcia JA**, Dreicer R, Pantuck AJ, et al. Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 240)
93. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DF, Soulie M, Eisenberger MA, Habibian M, Dreicer R, **Garcia JA**, Hussain M, Kohli M, Vogelzang NJ, Picus J, DiPaola RS, Sweeney C. Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 136)
94. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard DF, Dreicer R, Hahn NM, **Garcia JA**, Hussain M, Shevrin DH, Eisenberger MA, Kohli M, Wong YH, Cooney MM, Vogelzang NJ, Picus J, DiPaola RS, Sweeney C. Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D). *J Clin Oncol* 35, 2017 (suppl 6S; abstract 137)
95. Jarrard DF, Chen YH, Liu G, Carducci MA, Eisenberger MA, Wong YN, Hahn NM, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin DH, Hussain M, **Garcia JA**, DiPaola RS, Sweeney C. Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHARTED trial. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 181)
96. **Garcia JA**, Dreicer R, Pantuck AJ, et al. Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial. *J Clin Oncol* 35, 2017 (suppl; abstr 5041)
97. Ornstein MC, Diaz-Montero CM, Rayman PA, Elson P, Haywood S, Kim JS, Pavicic PG, Finke J, Rini BI, Stephenson AJ, Lamenza M, Dann P, Schach K, Devonshire S, Ko JS, Fergany AF, Ernstoff MS, Hoimes CJ, **Garcia JA**, Grivas P. Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC). *J Clin Oncol* 35, 2017 (suppl; abstr 4548)
98. Joshin VS, Reynolds J, Elson P, Magi-Galluzzi C, McKenney J, Smith KS, Shadrach B, Isse K, Saunders LR, Hu M, Tendulkar RD, Stephenson AJ, Fergany AF, Abazeed M, Rini BI, **Garcia JA**, Lee B, Mian OY, Grivas P. Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype. *J Clin Oncol* 35, 2017 (suppl; abstr 4529)
99. Ornstein MC, Diaz-Montero CM, Rayman PA, Elson P, Haywood S, Kim JS, Pavicic PG, Finke J, Rini BI, Stephenson AJ, Lamenza M, Dann P, Schach K, Devonshire S, Ko JS, Pascal GP, Ernstoff MS, Hoimes CJ, **Garcia JA**, Grivas P. Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial

- carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (ICI). *J Clin Oncol* 35, 2017 (suppl; abstr e16005)
100. Almassi N, Gao T, Lee B, Stein R, Pascal-Haber G, Ornstein MC, Rini BI, Gilligan TD, **Garcia JA**, Stephenson AJ, Grivas P. Neoadjuvant impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 457)
 101. Ciezki JP, Reddy CA, Mian OY, **Garcia JA**, Klein EA, Ulchaker J, Angermeier K, Campbell SC, Stephenson AJ. The importance of the need for better systemic therapy in the definitive treatment of high-risk prostate cancer regardless of whether the initial treatment modality was external beam radiation, I-125 brachytherapy, or radical prostatectomy. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 65)
 102. Koshkin VS, Barata PC, Zahor H, Rybicki LA, Almassi N, Redden AM, Fergany AF, Kaouk J, Pascal-Haber G, Stephenson AJ, Martin A, Allman KD, Beach J, Ornstein MC, Gilligan TD, **Garcia JA**, Rini BI, Grivas P. Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 446)
 103. Koshkin VS, Reynolds J, Elson P, McKenney J, Isse K, Saunders LR, Hu M, Stephenson AJ, Fergany AF, Lee B, Rini BI, **Garcia JA**, Grivas P. Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 452)
 104. Mendiratta P, Barata PC, Koshkin VS, Belcher A, McKenney J, Schach K, Isharwal S, Lee B, Stephenson AJ, Pascal-Haber G, Rini BI, Gilligan TD, Ornstein MC, **Garcia JA**, Grivas P. Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 439)
 105. Ornstein MC, Stephenson AJ, Elson P, Tayler AJ, Profusek P, Allman KD, Barata PC, Magi-Galluzzi C, Fergany AF, Stein R, Fareed K, Pascal-Haber G, Campbell SC, Kaouk J, Grivas P, Rini BI, Klein EA, Garcia JA. Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 88)
 106. Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG, Finke J, Barata PC, Lamenza M, Devoshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, **Garcia JA**, Gilligan TD, Ornstein MC, Grivas P. Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 454)
 107. Emamekhoo H, Alyamani M, Park S, Taylor J, Almassi N, Upadhyay S, Tyler AJ, Berk M, Hyan T, Grivas P, Rini BI, Garcia JA, Auchus RJ, Sharifi N. HSD3B1 genotype and abiraterone (Abi) metabolites in patients (pts) with prostate cancer (PCa). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 325)
 108. Emamekhoo H, Barata PC, Magi-Galluzzi C, Berk M, Taylor J, Tyler AJ, Rini BI, Grivas P, Gilligan TD, Ornstein MC, Stephenson AJ, Klein EA, Kaouk J, Pascal-Haber G, Sharifi N, **Garcia JA**. *J Clin Oncol* 36, 2018 (suppl 6S; abstr TPS155)
 109. Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG, Finke J, Barata PC, Lamenza M, Devoshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, **Garcia JA**, Gilligan TD, Ornstein MC, Grivas P. Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB). *J Clin Oncol* 36, 2018 (suppl 5S; abstr 109)
 110. Petrylack DP, Drake CG, Pieczonka CM, Corman JM, **Garcia JA**, Dunshee C, Van Mouwerik T, Tyler RC, Chang NN, Quinn D. Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 246)
 111. Chen YW, Tullio K, Ornstein MC, Grivas P, **Garcia JA**, Rini BI. The impact of facility case volume on overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 590)
 112. Ornstein MC, Calabrese C, Wood LS, Kirchner E, Tyler AJ, Profusek P, Allman KD, Kotzias A, Grivas P, Garcia JA, Calabrese L, Rini BI. Rheumatologic immune-related adverse events (irAE) in patients (pts) with genitourinary (GU) malignancies treated with immune checkpoint inhibitors (CPI). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 652)
 113. Barata PC, Emamekhoo H, Mendiratta P, Gopalakrishnan D, Koshkin VS, Tyler AJ, Ornstein MC, Grivas P, Gilligan TD, Rini BI, Kyriakopoulos C, **Garcia JA**. Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 305)
 114. Mendiratta P, Loehr A, Simmons A, Barata PC, Klek S, Pritchard A, Emamekhoo H, Funchain P, Sohal D, Ali SM, Gilligan TD, Ornstein MC, **Garcia JA**, Rini BI, Grivas P. Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 447)
 115. Barata PC, Koshkin VS, Mendiratta P, Gopalakrishnan D, Karafa M, Allman KD, Martin A, Beach J, Profusek P, Tyler AJ, Wood LS, Ornstein MC, Gilligan TD, **Garcia JA**, Rini BI, Grivas P. Atezolizumab (atezo) and subsequent

- therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 432)
116. Barata PC, Gomez de Liano A, Mendiratta P, Crolley V, Szabados B, Wood LS, Zanick B, Allman KD, Tyler AJ, Martin A, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Powles T, Rini BI. Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 613)
 117. Barata PC, Kotecha R, Mendiratta P, Juloori A, Angelov A, Chao ST, Elson P, Koshkin VS, Ornstein MC, Gilligan TD, Grivas P, Wood LS, Rini BI, **Garcia JA**. The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 36, 2018 (suppl 6S; abstr 599)
 118. Corman J, Petrylak DP, Drake CG, Pieczonka CN, Karsh LI, Concepcion RS, Garcia JA, Dunshee CJ, Mouwerik TV, Tyler RC, Chang NN and Quinn DI. Sipuleucel-T (SIP-T) with enzalutamide (ENZ) (STRIDE): Clinical outcomes in patients with metastatic castration-resistant prostate cancer (MCRPC) by baseline (BL) prostate-specific antigen (PSA) quartiles. *The Journal of Urology*, Volume 199, Issue 4, e306 - e307
 119. Corman J, Petrylack DP, Drake CG, Pieczonka CM, Karsh L, Concepcion RS, **Garcia JA**, Dunshee CJ, Mouwerik TV, Tyler RC, Chang NN, Quinn DI. PD14-06 Sipuleucel-T (SIP-T) with enzalutamide (ENZ) (STRIDE): Clinical outcomes in patients (Pts) with Metastatic castration-resistant prostate cancer (MCRPC) by baseline (BL) prostate-specific antigen (PSA) quartiles. *The Journal of Urology*, Vol. 199, Issue 4, e306–e307
 120. Bryce AH, ChenYH, Liu G, Carducci MA, Jarrard DF, **Garcia JA**, Dreicer R, Hussain M, Eisenberger MA, Kohli M, Hahn NM, Plimack ER, Vogelzang NJ, Picus J, DiPaola RS, Harshman LC, Sweeney C. Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial. *J Clin Oncol* 36, 2018 (suppl; abstr 5046)
 121. Nelson AN, Opneja A, Nezami BG, Ponksy LE, Wright MD, Mergler P, Kyasaram RK, Eitman C, Patel K, Macleannan G, Cooney MM, Grivas P, Barata PC, **Garcia JA**, Fu P, Hoimes CJ. Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC). *J Clin Oncol* 36, 2018 (suppl; abstr e16523)
 122. Gupta R, Ornstein MC, Gul A, Allman KD, Ball J, Wood LS, **Garcia JA**, VonMerveldt D, Hammers HJ, Rini BI; Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC). *J Clin Oncol* 37, 2019 (suppl 7S; abstr 659)
 123. Fallah J, Diaz-Montero CM, Rayman PA, Wei W, Sheng IR, Finke J, Kim JS, Pavicic PG, Dann P, Company D, Stephenson AJ, Campbell S, Haber GP, Lee BH, Mian OY, Gilligan TD, Rini BI, **Garcia JA**, Grivas PG, Ornstein MC. Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy. *J Clin Oncol* 37, 2019 (suppl 7S; abstr 437).
 124. Sheng IR, Diaz-Montero CM, Rayman PA, Wei W, Fallah J, Finke J, Kim JS, Pavicic PG, Lamenza M, Dann P, Company D, Stephenson AJ, Campbell S, Haber GP, Lee BH, Mian OY, Gilligan TD, Rini BI, **Garcia JA**, Grivas PG, Ornstein MC. Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS). *J Clin Oncol* 37, 2019 (suppl 7S; abstr 436).
 125. Mian OY, Abu-Gheida I, Kotecha R, Weller MA, Reddy CA, Kupelian P, Ornstein MC, Gilligan TD, **Garcia JA**, Rini BI, Stephenson AJ, Klein EA, Shah C, Ciezki JP, Stephans KL, Tendulkar RH. Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction). *J Clin Oncol* 37, 2019 (suppl 7S; abstr 78).
 126. Gupta R, Ornstein MC, Gul A, Allman KD, Ball J, Wood LS, **Garcia JA**, VonMerveldt D, Hammers HJ, Rini BI; Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC). *J Clin Oncol* 37, 2019 (suppl 7S; abstr 659). *J Clin Oncol* 37, 2019 (suppl; abstr e16084).
 127. Sheng IY, Yu-Wei Chen, Ornstein MC, Gilligan TD, Rini BI, **Garcia JA**; Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration. *J Clin Oncol* 37, 2019 (suppl; abstr 5071).